SKC's AMNOG orphan tracker records the most important changes to all orphan drug procedures during and after the AMNOG for an efficient overview on a bimonthly basis.
Highest added benefit, negotiated rebate and much more
The AMNOG orphan tracker provides all essential information about
- New AMNOG orphan drug procedures (active ingredient, trade name, reason for submission, indication)
- Completed AMNOG orphan drug procedures (active ingredient, trade name, indication, highest additional benefit) and
- New rebates for AMNOG orphan drug procedures (active ingredient, trade name, indication, highest added benefit, negotiated rebate)
The SKC Insights offer you further details on exciting AMNOG analyses.
The analyses are generated by data from SKC's proprietary MAIS database.
Download
You would like to download the orphan tracker free of charge? Please enter your contact details in the form. After confirming this, you will immediately receive the link to your chosen edition of the orphan tracker.
AMNOG orphan tracker November / December 2024
Eight drugs in nine procedures were negotiated – with BMS choosing to opt out Abecma® of the German market.
AMNOG orphan tracker September / October 2024
Are companies that actively engage in the orphan drug landscape in Europe by participating in the WODC more successful in the negotiations of the reimbursement amount?
AMNOG orphan tracker July / August 2024
Kimmtrak® received an additional 1% net ATC rebate after confirming its considerable added benefit in the re-assessment after exceeding the 30 million € threshold.
AMNOG orphan tracker May / June 2024
Out of the 12 newly initiated procedures, 6 are for Adcetris® due to exceeding the 30 million € sales threshold. Only one new rebate was negotiated.
AMNOG orphan tracker March / April 2024
Out of the five newly initiated procedures, two are first submissions. In addition, Abecma® is being reassessed in its first indication after exceeding the 30 million € threshold and concurrently submitted for an earlier treatment line.
AMNOG orphan tracker January / February 2024
Out of the eight newly initiated procedures, five are first submissions. In addition, Polivy® is being reassessed in its both indications after exceeding the 30 million € threshold.
AMNOG orphan tracker November / December 2023
19 new procedures were initiated under the AMNOG, five of them for Kaftrio®. Also, only one procedure has been started as an initial submission.
AMNOG orphan tracker September / October 2023
With new rebates for nine different active ingredients, most negotiations for orphan drugs were concluded in September and October, including the re-evaluation of the ATMP Luxturna®.
AMNOG orphan tracker July / August 2023
ATMPs continue to appear in the AMNOG landscape: for one ATMP each, a new trial has been started (Yescarta®) and completed (Carvykti®) and a rebate has been negotiated (Yescarta®).
AMNOG orphan tracker May / June 2023
The Federal Joint Committee (G-BA) demanded a routine practice data collection for Hemgenix®, two AMNOG procedures have been completed and Novartis announced that the EU approval for Adakveo® will be withdrawn.
AMNOG orphan tracker March / April 2023
ATMPs are becoming ever more present: A new ATMP procedure has been launched with Ebvallo®. Furthermore Roctavian® and Tecartus® were both given a non-quantifiable additional benefit and a reimbursement amount was set for Abecma®.
Full Market Access
Hands-on support throughout the whole process: from strategic positioning all the way to price negotiation, we accompany you seamlessly.
Strategic Pricing & Pricing Negotiations
Gain confidence for your decisions with us! We analyze with you individual pricing mechanisms and the European reference price system.
to the top